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Abstract: Cranberry consumption has shown prophylactic effects against urinary tract 
infections (UTI), although the mechanisms involved are not completely understood. In this 
paper, cranberry phenolic compounds and their potential microbial-derived metabolites 
(such as simple phenols and benzoic, phenylacetic and phenylpropionic acids) were tested 
for their capacity to inhibit the adherence of uropathogenic Escherichia coli (UPEC) 
ATCC®53503™ to T24 epithelial bladder cells. Catechol, benzoic acid, vanillic acid, 
phenylacetic acid and 3,4-dihydroxyphenylacetic acid showed anti-adhesive activity against 
UPEC in a concentration-dependent manner from 100–500 µM, whereas procyanidin A2, 
widely reported as an inhibitor of UPEC adherence on uroepithelium, was only statistically 
significant (p < 0.05) at 500 µM (51.3% inhibition). The results proved for the first time  
the anti-adhesive activity of some cranberry-derived phenolic metabolites against UPEC  
in vitro, suggesting that their presence in the urine could reduce bacterial colonization and 
progression of UTI. 
Keywords: UPEC; uropathogenic Escherichia coli; UTI; urinary tract infection; T-24 cells; 
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Uropathogenic Escherichia coli (UPEC) is responsible for 70%–90% of urinary tract infections 
(UTI). On its wall, strains of uropathogenic E. coli have structures called fimbriae that support adhesins, 
by means of which they join to the receptors of the uroepithelial cells. The most common virulence factor 
encoding gene in the UPEC strains is the gene for type 1 fimbriae, which are important for bladder 
colonization with a prevalence of 89%–95%. However, the type P-fimbriae encoded by the papG  
gene are more prevalent among strains that cause invasive and persistent UTI [1,2]. The recurrence of  
such infections despite antibiotic treatment, as well as the morbidity associated with them, has prompted 
the exploration and assessment of therapeutic alternatives to the standard antibiotic treatment [3].  
The prophylaxis for new and recurrent UTI by anti-adhesive compounds is coming more and more into 
experimental and clinical research focus. An optimized anti-adhesive entity should interact more or less 
specifically with adhesins of the pathogen, leading to a significant inhibition of the docking process 
between pro- and eukaryotic cells and further minimization of the invasion or infection of the  
epithelial cells [4,5]. 
Consumption of cranberry (Vaccinium macrocarpum) has been widely recommended for prophylaxis 
against UTI and is reputed to give symptomatic relief from these infections [6,7]. Numerous clinic 
studies have been carried out to evaluate the preventive effect of cranberry against UTIs, including 
several recent meta-analyses [8,9]. However, there is some current controversy about the clinical efficacy 
and cost effectiveness of cranberry supplements to decrease the risk of UTI due to the variability found in 
different clinical studies, although this variability has been attributed to different cranberry products and 
doses and lack of mechanistic guidance for the selection of subjects and study [8,10]. On the other hand, 
the mechanisms implied in the preventive effects of cranberry consumption against ITU are not 
completely established; one leading hypothesis is that cranberry components and/or their direct 
metabolites would operate in the phase of bacterial adherence to the uroepithelial cells, disabling or 
inhibiting the adherence of uropathogenic E. coli and, therefore, preventing bacterial colonization and 
progression of UTI. Moreover, cranberries are supposed to reduce UTI-related symptoms by suppressing 
inflammatory cascades as an immunologic response to bacteria invasion [7]. 
The red cranberry is rich in several groups of phenolic compounds, especially flavonols  
(200–400 mg/kg), anthocyanins (136–1710 mg/kg) and proanthocyanidins (PACs) (4188 mg/kg). 
Besides polyphenols, other phytochemicals occurring in cranberries are terpenes, organic acids, complex 
carbohydrates and sugars [6]. Among all of these cranberry components, A-type proanthocyanidins 
(PACs) seem mainly responsible for these preventive effects against UTI [6,11]. Both A- and B-type 
PACs are polymers of flavan-3-ol units bound through C-4 (upper unit)/C-6 or C-8 (lower unit) bonds, 
but only A-type PACs exhibit at least an additional ether type bond (C-2 (upper unit)-O-C-7  
(lower unit)). It is known that PACs are poorly absorbed in the small intestine, reaching the colon where 
they are catabolized by the gut microbiota to give rise to a great battery of phenolic metabolites that can 
be further absorbed and also secreted in the feces [12,13]. After the intake of B-type proanthocyanidins, 
present in grape seeds among other sources, urine has been evidenced to contain conjugates  
(i.e., glucuronides, O-methyl ethers and sulfates) of phenolic acids (i.e., phenylpropionic, phenylacetic, 
benzoic and cinnamic acids) and other metabolites derived from the action of the microbiota, as well as 
other compounds derived from phase-I and phase-II metabolism, although the catabolism pathways 
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involving these polymers are not fully elucidated [14]. Knowledge of the metabolism of A-type 
proanthocyanidins is less advanced [15]. Nevertheless, a recent study has reported the presence of  
A2-dimers in human urine after cranberry juice consumption [16]. Furthermore, some studies have 
reported the presence of different phenolic acids and other metabolites in urine collected after 
consumption of different cranberry products by healthy volunteers [16–18]. 
Cell culture methodologies have been used as an approach to studying the adherence/anti-adherence 
properties of E. coli strains in relation to UTI [3,5,19–21]. Studies on cell cultures have also evidenced 
anti-adhesive capacity against UPEC of urine samples collected after consumption of cranberry  
extracts [20,22,23]. Cranberry extracts and some of their components (e.g., procyanidin A2) have also 
been tested for E. coli anti-adhesive activity [3,24,25], although it is unlikely that these structures will 
reach the uroepithelium in vivo. In order to look more deeply into the bacteria anti-adhesive effects of 
cranberry-derived phenolic metabolites in relation to UTI, we have assessed the anti-adhesive activity 
against UPEC of different phenolic acids and simple phenols known to derive from the microbial 
catabolism of proanthocyanidins and other polyphenols and have compared these values to those 
corresponding to monomeric and dimeric flavan-3-ols and phenolic extracts from cranberry and grape 
seeds. For this, we firstly optimized an adhesion method of UPEC ATCC®53503™ to the T24 epithelial 
bladder cell line in order to improve adhesion rates in the assays. Overall, this study helps to advance 
the understanding of how A-type PACs are breaking down to form metabolites with in vivo anti-adhesion 
activity in the urine. This study should be considered as a first step, and further research should be done 
to definitively determine that the concentrations of these metabolites that have anti-adhesion activity  
in vitro are physiologically relevant in vivo. 
2. Results 
In order to optimize the method for evaluating the adherence of UPEC ATCC®53503™ to T24 
epithelial cells, different initial inocula of E. coli (103, 105 and 108 CFU·mL−1) were tested, and it was 
finally concluded that the value of 108 CFU·mL−1 (1000:1 ratio of bacteria cells per epithelial cell) led 
to higher bacteria adherence rates (10%–14% of the total number of bacteria added initially). Using this 
bacteria inoculum, different incubation times of E. coli with phenolic extracts (from 30 min to 4 h) were 
tested. An incubation time of 1 h was selected in order to achieve slight improvement in the measurement 
of the inhibition of the adherence of UPEC ATCC®53503™ to T24 epithelial cells (data not shown). 
The optimized method was applied to a total of 16 phenolic compounds, including flavan-3-ols  
((−)-epicatechin) and dimeric procyanidins of A-type (A2) and B-type (B2), and microbial-derived 
metabolites, such as simple phenols (2), benzoic acids (5), phenylacetic acids (3) and phenylpropionic 
acids (3) (Figure 1). Inhibition of adherence of UPEC ATCC®53503™ to T24 uroepithelial cells was 
established by incubating constant numbers of uroepithelial cells and bacteria preincubated with 
phenolic compounds (at concentrations of 100, 250 and 500 µM) (Table 1). Antimicrobial and 
cytotoxicity activity determinations were also carried out, and the tested concentrations and times were 
harmless to pro- and eukaryotic cells (data not shown). In relation to flavan-3-ols, and as reported in the 
literature for other UPEC strains, our results showed statistically-significant (p < 0.05) inhibition of the 
adherence of UPEC ATCC®53503™ to bladder cells by procyanidin A2 ((−)-epicatechin-(4β-8,  
2β-O-7)-(−)-epicatechin) (51.3% at 500 µM) (Table 1). However, no inhibitory effect was observed  
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for procyanidin B2 ((−)-epicatechin-(4β-8)-(−)-epicatechin) or (−)-epicatechin at any of the 
concentrations tested (Table 1). 
 
Figure 1. Chemical structures of phenolic compounds tested for their anti-adhesive activity 
against uropathogenic Escherichia coli. 
Once the anti-adhesive activity of A-type proanthocyanidins (i.e., A2) against UPEC ATCC®53503™ 
was confirmed using our cell culture method, we tested other phenolic compounds known to derive from 
the microbial catabolism of proanthocyanidins and whose effect on UPEC adherence had not been studied 
before (Table 1). Regarding simple phenols, 1,2 dihydroxybenzene (catechol/pyrocatechol) was found to 
have a significant and concentration-dependent inhibitory effect against UPEC at all assayed concentrations. 
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The same was observed for other benzoic acids (benzoic and vanillic acids) and phenylacetic acids 
(phenylacetic and 3,4-dihydroxyphenylacetic acids), which all exhibited inhibition percentages ≥29% at 
500 µM. As seen for A2, gallic acid and 3-(3-hydroxyphenyl)-propionic acid only exhibited a significant 
inhibitory effect against UPEC adherence at the highest assayed concentration (500 µM). 
Table 1. Inhibition (%) of the adherence of E. coli ATCC®53503™ to ATCC®HTB4™ cells 
by phenolic compounds. 
Phenolic Compounds 
C (µM) 
100 250 500 
Flavan-3-ols 
Procyanidin A2 7.63 ± 20.53 −5.89 ± 10.42 51.3 ** ± 7.1 
Procyanidin B2 6.79 ± 22.15 10.0 ± 10.1 −14.7 ± 20.9 
(−)-Epicatechin −6.02 ± 21.95 −1.21 ± 20.76 −5.82 ± 23.28 
Simple Phenols 
1,2-Dihydroxybenzene (catechol/pyrocatechol) 17.0 * ± 10.4 26.0 * ± 17.0 33.2 ** ± 11.7
1,3,5-Trihydroxybenzene (phloroglucinol) −8.53 ± 10.55 17.6 ± 35.7 −8.15 ± 29.41 
Benzoic Acids 
Benzoic acid 16.5 * ± 12.9 23.3 ** ± 14.0 32.2 ** ± 11.4
3-Hydroxybenzoic acid 11.1 ± 30.4 17.0 * ± 9.1 −9.7 ± 36.3 
3,4-Dihydroxybenzoic acid (protocatechuic acid) 25.5 * ± 10.2 24.0 ± 31.8 9.44 ± 17.09 
4-Hydroxy-3-methoxybenzoic acid (vanillic acid) 18.3 ** ± 2.3 24.9 ** ± 4.0 29.2 ** ± 2.2 
3,4,5-Trihydroxybenzoic acid (gallic acid) −3.72 ± 14.96 19.7 ± 43.7 40.6 ** ± 20.2
Phenylacetic Acids 
Phenylacetic acid 33.5 * ± 28.7 39.0 ** ± 3.3 40.6 ** ± 10.1 
3-Hydroxyphenylacetic acid 15.0 ± 11.4 11.9 ± 21.8 19.4 ± 22.9 
3,4-Dihydroxyphenylacetic acid 23.6 * ± 13.6 32.5 * ± 22.2 37.0 ** ± 20.5
Phenylpropionic Acids 
3-Phenylpropionic acid −11.8 ± 27.2 14.7 ± 21.8 12.2 ± 13.6 
3-(3-Hydroxyphenyl)-propionic acid 10.2 ± 17.6 18.6 ± 25.4 30.5 * ± 27.4 
3-(3,4-Dihydroxyphenyl)-propionic acid 6.66 ± 10.63 1.19 ± 22.80 13.1 ± 15.4 
* Mean significantly different from zero (p < 0.05) using one-sample t-test; ** Mean significantly different 
from zero (p < 0.01) using one-sample t-test. 
In addition to phenolic standards, two phenolic extracts from cranberry and grape seed, respectively 
rich in A- and B-type proanthocyanidins, were tested for their anti-adhesive activity against UPEC 
ATCC®53503™ (Table 2). No antimicrobial and cytotoxic activity to pro- and eukaryotic cells was 
observed for these extracts at the tested concentrations (data not shown). In contrast to several studies 
that have shown an adherence inhibition for cranberry extracts [3,22,26], our results did not show 
significant anti-adhesive activity of either the cranberry or grape seed extracts against UPEC at 
concentrations of 200, 500 and 1000 mg·L−1 (Table 2). This was attributed to differences in the initial 
cranberry material and extraction procedures among extracts [27]. 
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Table 2. Inhibition (%) of the adherence of E. coli ATCC®53503™ to ATCC®HTB4™ cells 
by phenolic extracts. 
Phenolic Extracts 
C (mg/L−1) 
200 500 1000 
Cranberry extract −11.9 ± 13.0 −9.76 ± 8.65 −13.8 ± 16.5 
Grape seed extract 2.21 ± 9.01 −16.4 ± 28.9 −9.8 ± 15.8 
3. Discussion 
Consumption of cranberry (Vaccinium macrocarpum) is widely recommended for prophylaxis 
against urinary tract infections (UTI) in women. Several authors have previously reported that cranberry 
proanthocyanidins contain unusual double A-type linkages that may be important structural features in 
the anti-adherence process against UPEC [20,28]. Our study agreed with these previous studies, as it 
showed that procyanidin A2 exhibited a statistically-significant (p < 0.05) inhibition of the adherence of 
UPEC ATCC®53503™ to bladder cells, but no inhibitory effect was observed for procyanidin B2. 
Moreover, previous comparative studies between A-type and B-type proanthocyanidins have also  
shown minimal or no in vitro anti-adhesive activity against UPEC of B-type proanthocyanidins from 
grape seeds and other sources, in comparison to cranberry proanthocyanidins [24]. With regard to  
the mechanisms involved in this anti-adhesive effect, Gupta et al. [25] hypothesized that A-type 
proanthocyanidins either combine with P-fimbriae of bacterial cells or modify the structural entity of  
P-fimbriae, as they observed inhibition of adherence for both sensitive and multi-drug-resistant 
uropathogenic P-fimbriated E. coli bacteria [25]. 
During their passage through the intestinal tract, some polyphenols are absorbed in the small intestine, 
although in general, they are extensively metabolized by the colon microbiota to produce phenolic 
metabolites, including simple phenols, phenolic acids and other metabolites [12]. Different studies have 
shown that phase-I and phase-II metabolites derived from the metabolism of phenolic compounds absorbed 
at the intestinal level are excreted in urine after the first hours of intake, whereas microbial-derived 
metabolites are excreted in urine at longer times [16,18]. As far as we know, our results demonstrated 
for the first time the in vitro anti-adhesive activity against UPEC of some microbial-derived  
phenolic metabolites, apart from A2 and other A-type proanthocyanidins, whose activity has been widely  
reported. Among the metabolites tested, catechol, benzoic acid, vanillic acid, phenylacetic acid and  
3,4-dihydroxyphenylacetic acid showed anti-adhesive activity against UPEC in a concentration-dependent 
manner from 100–500 µM (Table 1). Although it was not possible to establish a consistent  
structure-activity relationship from the data obtained, the relevance of these findings is that phenolic 
acids and/or their conjugates derived from the microbial catabolism of A-type proanthocyanidins could 
contribute to the UPEC anti-adherence effects associated with the consumption of cranberry. 
The concentrations of the phenolic metabolites tested may be physiologically relevant. From the few 
studies about the phenolic metabolites in human urine after cranberry consumption [16–18], one can 
work out that the urine concentration of some phenolic acids can reach at least 50 µM, which is within 
the range considered in our study. The free forms of phenolic acids and other phenolic compounds have 
been identified in plasma and urine after the intake of cranberry in humans, although conjugated 
phenolics are indeed dominant species [18]. Specifically, different dihydroxybenzoic acid isomers have 
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been detected in untreated urine samples after an eight-week supplementation with cranberry  
capsules [17] and after a single dose of cranberry syrup [29]. As seen in this study for the free forms  
of certain phenolic acids, it is likely that their conjugated metabolites could inhibit UPEC adherence.  
As conjugated metabolites are not commercialized yet, we could not test them, but once available, future 
studies with glucuronidated, sulfated and methylated derivatives (for a review, see Rodriguez-Mateos  
et al. [13]) will lend valuable information about the potential of phenolic acid formulations in  
the prevention/treatment of UTI. Systematic protocols to synthesize phenolic conjugates are under 
development [30]. Another matter for further research is the mechanism(s) involved in the anti-adhesive 
activity against UPEC by cranberry-derived phenolics metabolites. In relation to this, Amalaradjou  
et al. [31] found that trans-cinnamaldehyde, a principal component in cinnamon oil, that also 
significantly inhibited UPEC attachment and invasion of urinary tract epithelial cells (at a concentration 
of 750 µM), decreased the expression of major genes involved in uropathogenic E. coli attachment and 
invasion of host tissue. 
Although some particular studies showed no significant preventive effects derived from cranberry 
consumption [23], the general appreciation of numerous clinic studies carried out by the scientific 
community is that cranberry can be seen as an alternative to low-dose antibiotics in UTI prophylaxis and 
that additional clinical research on UTI prevention using cranberry products is clearly warranted [10]. 
4. Experimental Section 
4.1. Phenolic Compounds, Phenolic Extracts and Other Chemicals 
Flavan-3-ols ((−)-epicatechin, (−)-epicatechin-(4β-8, 2β-O-7)-(−)-epicatechin (procyanidin A2) and 
(−)-epicatechin-(4β-8)-(−)-epicatechin (procyanidin B2)) were purchased from Extrasynthèse (Genay, 
France). Simple phenols and phenolic acids targeted in this study (n = 13) are shown in Figure 1 and 
were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA), Phytolab (Vestenbergsgreuth, 
Germany) or Extrasynthèse (Genay, France). Commercial powders of cranberry extract (Triarco Industries 
Inc. NJ, USA) and grape seed extract, Vitaflavan® (Les Dérives Resiniques & Terpéniques, S.A. Dax, 
France), were also assayed. Total phenolic content (mg of gallic acid equivalents/g) of the cranberry and 
grape seed extracts was 219 and 629, respectively; as measured by the Folin-Ciocalteu reagent (Merck, 
Darmstadt, Germany). Phenolic composition and antioxidant activity values of these extracts were 
reported elsewhere [27]. The remaining chemicals and reagents were obtained from Sigma-Aldrich Co., 
Ltd. (Poole, Dorset, UK). 
4.2. Preparation of Phenolic Solutions 
Stock standard solutions were prepared in Dulbecco’s phosphate-buffered saline solution (DPBS, 
Lonza, Walkersville, MD, USA) by weighing individual phenolic compounds to achieve a starting 
concentration of 2500 µM, and assayed solutions were prepared via serial dilutions. Cranberry and grape 
seed powders were dissolved in DPBS with 0.01% and 0.1% DMSO, respectively, at a concentration of 
10,000 µg·mL−1, and serial dilutions were prepared afterwards. All phenolic solutions were normalized 
to contain a maximum of 0.02% DMSO in the culture medium, which did not show any effect compared 
to untreated control cells. 
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4.3. Escherichia coli Strain and Growing Conditions 
The UPEC ATCC®53503™ strain that proved to give rise to P-fimbriae [32] was used in this study. 
It was obtained from the American Type Culture Collection (ATCC), and bacteriological growth media 
(TSB and TSA broths) were obtained from Scharlau (Barcelona, Spain). E. coli strains that express  
P-fimbriae, the virulence factor most convincingly implicated in the pathogenesis of UTI, mediate 
Gal(α1-4)Gal-specific binding to host surfaces via the adhesin molecule PapG [2]. It was kept frozen at 
−70 °C in a sterilized mixture of glycerol in culture medium (20% v/v). The contents of thawed cryovials 
were added to the medium and grown overnight at 37 °C. Overnight cultures were harvested by 
centrifugation (10,000× g, 10 min, 4 °C) and resuspended in DPBS at a concentration of about 106 and 
108 CFU·mL−1 for antibacterial and adherence assays, respectively. 
4.4. Antibacterial Activity Assay 
The antibacterial assays were performed using the method of García-Ruiz et al. [33]. Inhibition of  
E. coli growth by phenolic compounds and extracts was determined by the microtiter dilution method, 
using serial double dilutions of the antimicrobial agents and initial E. coli inocula (106 CFU·mL−1). 
Bacteria growth was determined by reading the absorbance at 600 nm. Growth inhibitory activity was 
expressed as a mean percentage (%) of growth inhibition with respect to a control without antimicrobial 
extract. Assays were conducted in triplicate. 
4.5. Cell Culture 
We used T24 cells (ATCC®HTB4™), an uroepithelial cell line derived from transitional bladder 
carcinoma, as they have been shown to be similar to primary human bladder epithelial cells [34]. T24 
bladder cells were grown and maintained in McCoy’s 5A medium (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% (v/v) fetal bovine serum at 37 °C in an atmosphere of 5% CO2/95% air at 
constant humidity. For the experiments, cells were seeded in 96- or 24-well tissue plates and grown 
approximately for 24 h to enable cell attachment and to obtain a cell monolayer. 
4.6. Cytotoxicity Assay/Cell Viability 
Cytotoxicity of the tested compound against T24 cells was performed using the colorimetric  
3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay [35], which is based  
on the reduction of the dye MTT to formazan, an insoluble intracellular blue product, by cellular 
dehydrogenases. Briefly, T24 cells seeded in a 96-well plate the previous day were incubated with 
phenolic compounds and extracts for 24 h. Then, the supernatant was removed, the monolayer washed 
with DPBS, and MTT was added to each well (0.5 mg·mL−1) and incubated for 3 h at 37 °C. Absorbance 
was measured at 570 nm with a plate reader (Multiskan FC Thermo Scientific, Newington, NH, USA). 
Assays were conducted in triplicate. The absorbance ratio between cell culture treated with the extracts 
and the untreated control multiplied by 100 represents cell viability (percentage of control). 
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4.7. Adherence Assay 
UPEC overnight cultures (108 CFU·mL−1) were incubated with the same volume of each phenolic 
compound/extract for 1 h, at 37 °C, in agitation (180 rpm). Then, confluent T24 cell monolayers  
(5 × 105 cells/well) were washed with DPBS solution to eliminate antibiotic and overlaid with  
0.5 mL of the UPEC bacteria pre-incubated with each phenolic compound/extract or with DPBS 
(control). After 1 h of incubation at 37 °C under 5% CO2 atmosphere, wells were softly washed  
with DPBS solution to remove unbound bacteria. Cells and adhered bacteria were then detached by 
trypsinization and sonicated in an ultrasonic sonication bath (3 pulses, 10 s on, 3 s off) at 40 kHz to 
recover bacteria associated with cells. Bacterial counts (CFU·mL−1) were carried out by serial dilution 
plate method in TSA plates. Assays were carried out in triplicate, and experiments were repeated twice. 
The adherence percentage (%) was calculated as the number of adhered bacteria (CFU·mL−1) relative  
to the total number of bacteria added initially × 100. The percentage of inhibition by a phenolic 
compound/extract was calculated as [1 − (% Adherencesample/% Adherencecontrol)] × 100. 
4.8. Statistical Analysis 
A one-sample t-test was used to evaluate whether the inhibition of adherence of UPEC 
ATCC®53503™ to T24 uroepithelial cells was different from 0%. The STATISTICA program for 
Windows, Version 7.1 (StatSoft Inc., 1984–2006, www.statsoft.com), was used for data processing. 
5. Conclusions 
This paper reports valuable information about the inhibitory activity against UPEC adherence to 
uroepithelial cells by cranberry components and their potential urinary metabolites. An optimized 
method to study the adherence of UPEC ATCC®53503™ to T24 epithelial bladder cells was described. 
Our results demonstrated for the first time the in vitro anti-adhesive activity against UPEC of other  
low molecular weight phenolic metabolites (i.e., simple phenols and phenolic acids), although it was  
not possible to establish a consistent structure-activity relationship from these data. This approach, 
considering pure standard phenolic compounds, confirms the protective action against UPEC adherence 
by phenolic metabolites generated from the metabolism of cranberry and, therefore, expands the 
beneficial effects of these metabolites in UTI prophylaxis. 
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